We’re incredibly proud to announce that CSI has once again achieved the Platinum   EcoVadis  rating, for the second year in a row!  This places us in the top 1% globally for sustainability, ethics and corporate responsibility. It’s an incredible accomplishment and a testament to the values we live by every day. A huge thank you to our dedicated team for making this possible, your commitment continues to set us apart.

On the 12th day of Christmas CSI gave to me…   Twelve reasons sponsors trust CSI, all year long! On the 1st day of Christmas CSI gave to me…  Direct Manufacturer Access! Receive faster timelines and documentation thanks to CSI’s direct accounts with global pharma leaders. Reach out to CSI for a sourcing consultation, no matter how big or small your request. On the 2nd day of Christmas CSI gave to me… Unmatched sustainability; with an EcoVadis Platinum rating, putting us in the top 1% of companies worldwide. We are committed to decarbonisation and work hard towards a sustainable environment. We are proud to have been awarded the Platinum Award by EcoVadis, 2 years in a row. On the 3rd day of Christmas CSI gave to me… Support with US government-funded trials. CSI are BARDA &  SAM.gov  approved, qualified to support US government-funded trials, BARDA, NIH, DoD and more. Reach out to CSI for a US sourcing consultation. On the 4th day of Christmas CSI gave to me… Global Documentation and Compliance Support! CSI has your regulatory paperwork covered with translations, such as Certificates of Analysis (CoAs) for exports, Statements of Authenticity (SoAs) or Batch release Statements. CSI also has a responsive, in-house Quality team. Schedule a sourcing consultation with CSI’s regulation and compliance experts. On the 5th day of Christmas CSI gave to me… A Fully Scientific Team, Built to Understand Your Study Needs. At CSI, every member of our team holds a science degree (Bachelor’s or higher), ensuring true scientific rigor in protocol analysis, product selection and clinical supply strategy.  We speak your language! Need expert support in comparator sourcing? Contact CSI for a sourcing consultation. On the 6th day of Christmas CSI gave to me… Women-Owned Leadership Powering clinical trials with diversity in leadership, CSI is proudly women-owned; 65% of our workforce are women. We are multicultural and multi-faith, celebrating and respecting our differences; united in our dedication to our clients. Reach out to CSI for a sourcing consultation with a diverse, women-owned partner. On the 7th day of Christmas CSI gave to me… Rapid Study Start-Up Times Need comparator in weeks, not months?  Clinical Services International (CSI)  is well-versed in dealing with tight timelines, with many success stories such as CSI’s streamlined Venetoclax and Azacitidine supply across 17 countries in record time. Why not reach out to CSI with your requirements to see if we can shorten the lead-times? On the 8th day of Christmas CSI gave to me… Agile Sourcing Teams CSI adapts to your protocol whether you require single-batch, multi-batch, staggered supply, we’ve got you.  Read how CSI delivered mission impossible by sourcing specific tested batches of an expensive oncology product from several European markets. Try us out for a sourcing consultation, however complex your requirements. On the 9th day of Christmas, CSI gave to me… Comparator Strategy Guidance Need advice on blinded vs open-label sourcing? Need support with protocol analysis or purchasing runs?  Clinical Services International (CSI)  provides scientific & operational guidance, to overcome comparator sourcing challenges. Contact CSI for a sourcing consultation, however complex your requirements. On the 10th day of Christmas, CSI gave to me… Logistical Expertise. From -80°C, 2-8C biologics, to ambient tablets, CSI delivers precise temperature control anywhere, connected with TraceLink to ensure full supply-chain visibility. Reach out to CSI for a sourcing consultation with a logistically savvy partner:  www.csint.com/contact-us On the 11th day of Christmas CSI gave to me…  A dedicated clinical trial supply partner, trusted by the top Pharma/Biotechs. From emerging biotech to global sponsors, CSI is the partner behind successful trials worldwide. This season, bring peace of mind to your trial timelines.  Reach out to the clinical trial supply experts, your success is our success.

Recent headlines around proposed US tariffs on European countries highlight just how volatile the global trade environment remains. As reported this week  in Fierce Pharma , potential new duties on several European nations raised questions about the future of US–EU trade relations and potential impacts on pharmaceuticals. For sponsors running global clinical trials, this kind of uncertainty can translate into real operational risk: fluctuating costs, sourcing delays, and regulatory complexity across borders. That’s where Clinical Services International (CSI)  comes in. CSI supports clinical trial studies by providing robust, flexible comparator and ancillary sourcing strategies, designed to withstand geopolitical and trade disruptions. With direct relationships across global manufacturers and experience operating through our UK, EU, and US entities, we help sponsors mitigate tariff exposure, maintain compliant supply chains, and protect study timelines; even when policies shift unexpectedly. In an environment where trade frameworks and import duties can change rapidly, having a trusted, globally experienced supply partner is critical. CSI helps ensure your clinical trials stay on track, no matter how complex the global landscape becomes. Contact CSI now  with your study requirements

Client:  Mid-size biotech conducting multiple clinical trials Challenge: The client required a large quantity of Humira (adalimumab) for several upcoming studies. High costs and limited availability were putting pressure on study budgets and timelines. Solution: CSI leveraged its industry insight and direct relationships with the manufacturer to provide access to a high-quality adalimumab biosimilar. This saved the client a staggering 50% on price . By carefully coordinating sourcing and supply, we ensured uninterrupted study timelines while maintaining compliance. Results: Cost savings:  Thousands of dollars saved with biosimilar adalimumab compared to brand-name Humira. Timely supply:  No delays in trial enrolment or dosing schedules. Seamless support:  Certificates of Analysis (CoAs), first-leg documents and stability data were provided. Conclusion: By partnering with CSI, the client was able to reduce drug costs significantly without compromising on quality or timelines, demonstrating the value of strategic comparator sourcing for clinical trials.

CSI's Managing Director, Vanessa Dekou PhD, MBA, hosted an inspiring talk at Imperial College London 's Entrepreneurship course, sharing the story behind the creation of Clinical Services International. By identifying a clear gap in the clinical supply market, Vanessa built CSI with a vision to deliver smarter, more agile solutions for global clinical trials. The session was highly engaging and extremely well received, sparking curiosity and ambition among the next generation of scientific and entrepreneurial minds. If you’re looking for expert clinical supply support, reach out to CSI for a quote: www.csint.com/contact-us

From all of us at  Clinical Services International (CSI) , we wish you a joyful and peaceful holiday season! We’ve created a special Christmas video to celebrate the incredible partnerships, teamwork and milestones we’ve achieved together.  Thank you to our clients, partners, and colleagues around the world for your continued trust and collaboration.

As we prepare for Q1 2026, sponsors and CROs face a shifting global landscape for clinical trial comparator sourcing that focuses on sustainability, diversity and fair pricing. With our EcoVadis Platinum certification, women-owned business status and full scientific team in place, CSI is well placed to support our partner’s supply chains. 1. Supply-chain volatility is real Clinical supplies are increasingly challenged by geo-political pressures, export controls, and manufacturing concentration. Add to that evolving regulatory expectations (global CoA requirements, tighter comparator traceability), and sponsors need a partner with well-established manufacturer relationships. CSI’s direct accounts with major manufacturers puts us in a strong position to support complex comparator supply and to help you meet critical timelines. 2. Regulatory and pricing policy shifts are reshaping the industry In the US, Donald Trump’s administration has renewed focus on the “most-favoured nation” (MFN) pricing model: tying US drug prices to those paid in other comparable countries . For example, a landmark deal between Pfizer and the US Government commits to aligning US prices with developed‐world benchmarks and expanding domestic manufacturing. What does this mean for trial sponsors? Branded comparator supply may become subject to pricing/launch shifts; companies may delay or reprioritize markets to protect pricing globally. Demand for transparency, documentation and supply reliability will increase for all parties to manage risk. Suppliers who can offer robust supply assurance, global-ready documentation and diversified sourcing will gain an advantage. 3. Why this matters for your 2026 pipeline With pipeline activity increasing (NMEs, ATMPs, biosimilars) and sponsors under timer pressure, the comparator sourcing window is tightening. A partner who can deliver import/export guidance, traceability and contingency planning is critical. At CSI we combine: End-to-end comparator supply support Global documentation (including via our certified scientific team) Sustainability, ethical sourcing and a women-owned organisational profile that meets many corporate supplier diversity mandates Direct manufacturer access to cut out unnecessary middle-men and reduce lead-times 4. Actionable next steps for sponsors Audit your comparator sourcing providers now : Do your current partners adhere to lead times and regulatory documentation requirements? Ask your comparator supplier : Can they guarantee CoAs for every shipment, global registration‐ready documentation and alternative supply routes if challenges such as shortages arise? Consider regulatory/policy headwinds : The evolving US pricing environment means some branded drugs may face launch delays or pricing adjustments. Factor this into your comparator selection discussions. Partner with a supplier who understands both science and logistics : From molecule sourcing to clinical packaging, CSI can overcome these complexities. At CSI, we are ready to support your study needs, whether global or US, novel comparator or established branded. With our SAM.gov and BARDA approvals, women-owned status, EcoVadis Platinum certification and full scientific team, you get a partner who understands the end-to-end challenges and can act as your supply-chain ally. Ready to map your comparator strategy for 2026? Try us out for a quote.

Oncology products monopolise the list of best-selling drugs. With a huge range of indications that is only growing, therapies become more specific to tumour or cell pathologies and increasing patient numbers. Several oncology products now have ‘blockbuster’ status where sales exceed $1 billion annually. This is relevant for clinical trials as more regulators require evidence of efficacy in comparison to the standard of care, which is likely to be one of the blockbuster products. A significant proportion of the late-stage clinical trial pipeline is in oncology indications as immunotherapies and next-generation biotherapeutics are gearing up for approval. This means that sponsors are having to fork out for these blockbuster products in order to run their trials more often. Keytruda (Pembrolizumab) and Opdivo (Nivolumab) Number 2 and number 11 respectively in annual sales of oncology products are Merck’s Keytruda ($7.2B) and BMS’s Opdivo ($1.8B) . They are both checkpoint inhibitors targeted towards Programmed cell Death protein 1 (PD-1 inhibitors) that is responsible for downregulating the immune system that prevents the immune system from killing cancer cells. As both products target the same pathway, they naturally compete in many indications (Table 1). Keytruda Opdivo ​Melanoma Melanoma (in combination with Yervoy) Non-small cell lung cancer (as monotherapy and combination) Non-small cell lung cancer Urothelial carcinoma Urothelial carcinoma Classical Hodgkin lymphoma Classical Hodgkin lymphoma Head and neck squamous cell carcinoma Squamous cell cancer of the head and neck ​ Advanced renal cell carcinoma (in combination with Yervoy) Table 1: Indications for Keytruda and Opdivo. This means for many therapies, it is the physician’s choice whether to use Opdivo (often in combination with Yervoy) or Keytruda. Keytruda has been more successful in part due to its higher efficacy among all groups and reduced toxicity. Both of these products are incredibly popular in clinical trials; a search on clinicaltrials.gov shows that there are 783 studies recruiting using Keytruda and 707 for Opdivo. Herceptin (Trastuzumab) and Mabthera (Rituximab) Roche’s Herceptin and Mabthera come in at number 3 and 5, selling $7B and $6.8B respectively. They are highly effective therapies for HER-2 positive breast cancer (Herceptin) and Non-Hodgkin’s Lymphoma (Mabthera), two of the most common and widely treated cancers. However, the financial success of these products is under threat. Biosimilars are increasingly becoming the standard of care and both have several licensed biosimilar drugs (e.g. Celltrion’s Herceptin biosimilar – Truxima). As more trials show equivalency in outcomes between the branded and biosimilar product, more purchasers will choose the cheaper option. On clinicaltrials.gov , there are 246 recruiting studies with Trastuzumab and 415 with Rituximab; a growing proportion of them will choose the biosimilar. No product is safe from the encroachment of biosimilars, #4 (Roche’s Avastin – $6.8B) is also under threat as Amgen’s Mvasi has been approved by the Food and Drug Administration (FDA). As these blockbuster products continue to increase their market share and more trials are running globally utilising these products, sourcing them has become a hugely important part of a successful clinical trial. All the products mentioned come at a significant cost, running into the thousands per dose. It makes sense then to partner with an expert in sourcing to ensure the most efficient, risk-free, and cost-effective solution possible. Clinical Services International is a trusted partner of leading Pharmaceutical and Biotechnology Companies, Clinical Research Organisations, and Contract Manufacturing Organisations. We are experts in sourcing licensed and unlicensed medicines for use in trials, ranging from eye drops to the most sought-after blockbuster therapies.

Clinical trials are the backbone of medical advancement, providing the essential data to bring new therapies from the laboratory to the clinic. However, the complexities and costs associated with clinical trial supplies have been rising, making it challenging for many organizations to navigate the process effectively. Outsourcing has emerged as a strategy for managing these sourcing challenges and driving success in clinical trials. Here’s how to leverage outsourcing to ensure your clinical trials are successful. 1. Understanding the Need for Outsourcing Clinical trials involve multiple stages, each with unique requirements that demand specialised knowledge of markets and resources. These stages include protocol analysis, product sourcing, manufacturing and distributing. By outsourcing, Pharma and Biotech's can access expertise that may not be available in-house, reduce operational costs, and focus on core competencies.   2. Choosing the Right Partners The success of outsourcing in clinical trials hinges on selecting the right partners. Clinical Research Organizations (CROs) and specialized solutions providers are among the typical partners. Here are key factors to consider when choosing outsourcing partners: Experience and Expertise : Look for partners with a proven track record in your therapeutic area. CSI has successfully supplied more than 1000 trials worldwide and we have the most comprehensive knowledge in oncology supplies. In addition, direct accounts with more than 95 pharmaceutical companies and a network of warehouses in 60 countries enables us to deliver the most demanding adaptive trial. Regulatory Knowledge : Ensure they have a deep understanding of the regulatory landscape in the regions where your trials will be conducted. CSI has outstanding regulatory expertise in-house and has conducted trials across 45 countries in Europe, North and South America and Asia. Cultural Fit and Communication : Effective collaboration requires partners who align with your organisational culture and communication style. CSI has recently been awarded the Platinum EcoVadis Award, highlighting our commitment to a sustainable and ethical future in clinical trials. 3. Defining Clear Objectives and Expectations Clear objectives and expectations are crucial for any outsourcing relationship, by defining the scope of work, timelines, deliverables and quality standards from the outset. CSI develops comprehensive contracts to formalize these expectations and ensure accountability. 4. Maintaining Oversight and Quality Control While outsourcing can offload significant work, maintaining oversight is essential. CSI establishes regular communication via bi-weekly meetings to monitor progress and address any potential issues promptly and manages performance against well-defined KPIs, mutually agreed 5. Leveraging Technology Technology can enhance the efficiency and effectiveness of outsourced clinical trials. CSI invests heavily in research and has several extensive in-house database systems that enable us to monitor all regulatory requirements all over the world and can proactively offer solutions to our clients.     6. Fostering Long-term Relationships Building long-term relationships with outsourcing partners can provide ongoing benefits, such as enhanced trust, better collaboration and improved efficiency in future projects. Investing in these relationships can lead to more seamless integration and a deeper understanding of each party’s requirements and priorities.     Conclusion When executed strategically, outsourcing is a powerful tool to drive success in the clinical trial supply chain. It allows organizations to tap into specialized expertise and reduce operational burdens. By choosing the right partners, Pharma and Biotech companies can offload some of the the complexities of clinical trial supply effectively and focus on bringing new life-saving therapies to market.

By Clinical Services International As a proud Women-Owned Business , Clinical Services International (CSI)  is committed to transforming the global clinical supply landscape while championing gender equity and social responsibility. Founded on the principles of scientific excellence, ethical sourcing and diversity, CSI  stands at the forefront of pharmaceutical procurement and supply solutions for clinical trials worldwide. Women-owned businesses are vital to the global economy, bringing fresh perspectives, inclusive leadership and resilience. At CSI , our team, comprised of highly qualified women in science, brings industry expertise and a personal commitment to the highest quality standards. CSI’s Managing Director, Vanessa Dekou, has always been passionate about building a company culture grounded in inclusivity, integrity, and empowerment. As a woman in science and business, she recognized early on the importance of creating a workplace where individuals feel safe, respected, and supported regardless of gender, background or role. Our status as a Women-Owned Organization  not only differentiates us in the marketplace, but also strengthens our partnerships with pharmaceutical and biotech companies that prioritize supplier diversity and ESG (Environmental, Social, Governance) values. Beyond business, CSI  is dedicated to giving back. We actively support women’s charities, including the Ladies Union of Drama in Northern Greece , a grassroots organization that provides shelter, food, and vocational support to women and children in need. Through funding, donations and awareness campaigns, CSI helps empower vulnerable women and promote gender equality on a global scale. Our clients trust CSI not just for our reliable sourcing of comparators and clinical trial supplies, but also for our integrity, inclusivity and commitment to meaningful impact. As we continue to grow, we remain focused on advancing healthcare access while elevating the role of women in life sciences and beyond. For companies seeking a trusted, values-driven partner in clinical supply, CSI is uniquely positioned to deliver. Learn more about CSI’s mission and impact at www.csint.com

As part of our ongoing commitment to excellence and continuous improvement, CSI is proud to announce the digitalization of our Quality Management System (QMS) through Simploud , a leading eQMS platform.   This transition marks an important milestone in enhancing both our customer and supplier experience, ensuring greater efficiency, transparency and compliance across our global operations.   Simploud ’s unified platform will streamline key quality processes (including CAPA management, audits and document control) supporting CSI’s mission to deliver the highest standards in clinical supply solutions.   This reinforces CSI’s dedication to quality and innovation as we continue to advance our operations.   For full details, read our announcement.

October is Breast Cancer Awareness Month and  Clinical Services International (CSI)  is wearing pink to show our solidarity with the cause. Pink is the colour of the ribbon that represents breast cancer awareness. Wearing pink on this day is a way to express support for breast cancer survivors, remember those lost to the disease and advocate for the progress in the fight against breast cancer. Reach out to CSI for your Breast Cancer studies, let's beat Breast Cancer together.